Navigation Links
TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Date:10/20/2008

LA JOLLA, Calif., Oct. 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced it initiated dosing of the first cohort of subjects in a Phase I multiple dose clinical trial of NGX426, the oral prodrug of its most advanced product candidate, tezampanel. The trial is designed to evaluate the safety, tolerability and pharmacokinetics of NGX426 when given once daily for five consecutive days. NGX426 has been safely administered to more than 150 healthy adults in single doses from 10 to 210 mg. Data from the multiple dose trial will support the development of NGX426 in chronic pain indications such as neuropathic pain.

The double-blind, placebo-controlled, Phase I multiple dose trial is being conducted at a single center in the United States. A total of 20 healthy male and female adult volunteers will be enrolled in two sequential dose-escalating cohorts and will receive once daily oral doses of placebo, 90 mg or 150 mg of NGX426 for five consecutive days. These same dose strengths of NGX426 are currently being evaluated by TorreyPines in a Phase I single dose capsaicin induced hyperalgesia trial to evaluate the analgesic effect of NGX426. Results from this single dose trial are expected to be announced in December 2008.

"We are pleased with our development progress for NGX426. This novel, oral, non-opioid product candidate could potentially address significant unmet needs in treating migraine and other forms of chronic pain such as neuropathic pain," said Ev Graham, acting chief executive officer of TorreyPines Therapeutics. "The multiple dose trial, as well as the ongoing Phase I capsaicin trial evaluating the analgesic effect of NGX426, will guide us in planning our Phase II program."

Tezampanel
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
2. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
3. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
4. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
5. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
6. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
7. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. TorreyPines Therapeutics Reports Third Quarter 2007 Results
10. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... NewsMakers in the Biotech Industry conference on Friday, ... Millennium Broadway Hotel & Conference Center in New ... be accessed at www.meipharma.com . A replay will be ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... half of Americans living with colorectal cancer will ... course of their disease. Radiofrequency ablation, a minimally ... tumor causing cancer cell death with minimal associated ... prolongation of their life by nearly three years, ...
... a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the year ended 2009 will be released on Tuesday, March 23, 2010 ... , ... ... ...
... , March 16, 2010 Elbit Imaging,(NASDAQ: EMITF ) ("Elbit Imaging" "Company") announced today that its,wholly-owned subsidiary, Elbit Medical Ltd., ... the Tel Aviv,Stock Exchange. , ... , ... ...
Cached Biology Technology:Living longer: Colon cancer patients gain time with radiofrequency ablation treatment 2Living longer: Colon cancer patients gain time with radiofrequency ablation treatment 3PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 2Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 3Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 4Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 5Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 6
(Date:9/18/2014)... ever starts a "frequent flyers" program, fruit flies surely ... laboratory has hosted increasing numbers of fruit fly research ... station in April, and another is scheduled launch to ... to launch in December. , Fruit flies are biomedical ... in space. Model organisms can reveal the basis for ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... tropical rabbitfish which have devastated algal forests in the ... entire Mediterranean basin if their distribution continues to expand ... study, by an international team of researchers led by ... Tomas of the Mediterranean Institute for Advanced Studies in ... ., Members of the team surveyed more than 1000 ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
... metal scaffolds inserted into blood vessels, to better deliver ... the risk of inflammation that often negates initial benefits. ... an extremely thin layer to bare metal surfaces, may ... make use of metallic implants. , Cardiologists frequently treat ...
... history's worst infectious diseases, but there are many more diseases ... society needs to confront to unlock the future promise of ... focus of a new report by the American Academy of ... been profound. Many diseases that formerly raged unchecked are ...
... flow of carbon through soil is ten times greater than the ... but until now how this happens was at best poorly understood. ... carbon. Now researchers at the University of Warwick have been able ... class of insects to expose the key underground carbon traffic system ...
Cached Biology News:Bare metal stents deliver gene therapy to heart vessels with less inflammation in animal studies 2Report focuses on challenges to unlocking future promise of vaccines 2Bugs expose underground carbon traffic system 10 times more important than fossil fuel burning 2
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
HyPro 20 system for slide hybridization. 20 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: